Francis Ferrante, MD
Pain Medicine · Los Angeles, CANPI 1972547511
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Purdue Pharma L.p. at 41.7% of the total. Reporting peaked in 2020 at $40,467 and has fallen 97.9% since, to $869 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $253.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Purdue Pharma L.p.$31K
- Avanos Medical$30K
- Medtronic$4K
- Boston Scientific$4K
- Nalu Medical, Inc.$2K
- Abbott$1K
- plus $2K from 18 others
Across 1 payment — averaging $410.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$410
What the payments were for
- Consulting fees$31,35042%
- Speaking & faculty fees$25,76134%
- Travel & lodging$3,5895%
- Food & beverage$14,51319%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Purdue Pharma L.p. | 1 | $31,350 |
| Avanos Medical | 35 | $30,435 |
| Medtronic(2 entities) | 73 | $4,210 |
| Boston Scientific | 62 | $3,528 |
| Nalu Medical, Inc. | 28 | $1,745 |
| Abbott | 39 | $1,487 |
| Saluda Medical Americas, Inc. | 7 | $389 |
| Vertiflex, Inc. | 7 | $333 |
| Painteq LLC | 3 | $289 |
| Vertos Medical, Inc. | 2 | $274 |
| Biotronik NRO, Inc. | 4 | $210 |
| Collegium Pharmaceutical, Inc. | 11 | $183 |
| Stimwave Technologies Incorporated | 5 | $171 |
| Relievant Medsystems, Inc. | 3 | $158 |
| Tersera Therapeutics LLC | 5 | $104 |
| Vertex | 3 | $92 |
| Stryker | 1 | $74 |
| Curonix LLC | 2 | $43 |
| GRT US Holding, Inc. | 1 | $31 |
| AbbVie | 1 | $29 |
| Nevro Corp. | 1 | $24 |
| Piramal Critical Care | 1 | $20 |
| Averitas Pharma Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXYCONTIN$31,350
- COOLIEF$17,831
- COOLIEF* COOLED RADIOFREQUENCY$10,574
- GENERATOR$1,700
- INTELLIS$1,484
- Nalu Neurostimulation System$1,119
- GENERAL PAIN MANAGEMENT$678
- SUPERION$629
- SYNCHROMEDII$488
- WaveWriter Alpha Prime 16$463
- ETERNA$451
- Proclaim IPG$303
- mild Device Kit$274
- RESTORE$268
- Superion ISS$222
- Superion Indirect Decompression System$172
- VANTA ADAPTIVESTIM$163
- PAINTEQ$161
- INTELLIS ADAPTIVESTIM$160
- KYPHON Balloon Kyphoplasty$159
How this compares
$75,214 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 31 | $26,561 |
| Oxycodone Hcl | 128 | $8,433 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 186 | $5,907 |
| Fentanyl | 32 | $3,564 |
| Morphine Sulfate ErMorphine Sulfate | 55 | $3,079 |
| Gabapentin | 113 | $2,807 |
| Lidocaine | 19 | $2,580 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 71 | $2,210 |
| Hydromorphone Hcl | 22 | $1,545 |
| Pregabalin | 24 | $928 |
| Naloxone Hcl | 18 | $854 |
| Baclofen | 18 | $836 |
| Duloxetine Hcl | 43 | $811 |
| Methocarbamol | 38 | $727 |
| Tramadol Hcl | 51 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Purdue Pharma L.p.Oxycontin | $31,350 | $26,56131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.
Other pain medicine in Los Angeles
- Myung YangLos Angeles$31K
- Philip DohLos Angeles$30K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.